Henry Schein, Inc. (NASDAQ:HSIC) reported fourth-quarter results on Tuesday that came in ahead of analyst expectations, with both earnings and revenue surpassing consensus estimates.
The healthcare solutions provider posted adjusted earnings per share of $1.34, above the consensus forecast of $1.30. Shares were little changed in after-hours trading following the announcement.
Quarterly revenue totaled $3.4 billion, exceeding analyst expectations of $3.34 billion and representing a 7.7% increase compared with the same period last year. Adjusted EPS rose 12.6% year-on-year from $1.19 recorded in the fourth quarter of 2024.
Sales growth was driven by 4.9% internal expansion, a 0.9% contribution from acquisitions and a 1.9% benefit from foreign exchange movements. “Our fourth-quarter sales reflect continuing momentum resulting in the highest sales growth in 15 quarters,” said Stanley M. Bergman, Chairman and Chief Executive Officer.
Performance was supported by strong equipment demand, with global equipment sales rising 12.2%, while specialty product sales increased 14.6%. Global dental distribution merchandise sales grew 6.4%, and medical distribution sales advanced 4.9%.
For fiscal 2026, Henry Schein guided adjusted earnings per share of $5.23 to $5.37, with the midpoint of $5.30 slightly above the analyst consensus estimate of $5.29. The company expects total sales to grow between 3% and 5% during the year.
Global Specialty Products delivered standout performance, posting 14.6% sales growth driven primarily by dental implant and endodontic products. Technology-related revenue increased 8.4%, reflecting stronger adoption of cloud-based software platforms and recently introduced solutions.
During the quarter, the company repurchased approximately 2.8 million shares for $200 million. Across full-year 2025, Henry Schein bought back 12.1 million shares with a total value of $850 million.